Summary.
Levodopa (LD) application improves motor symptoms in patients with Parkinson’s disease (PD) patients. Little is known on further effects of LD, which induced lower plasma levels of cortisol and lower serotonergic activity in certain brain areas of fish. Objectives of this trial were to analyse levels of cortisol, LD and 3-O-methyldopa (3-OMD) after administration of LD/benserazide in long term treated PD patients. 12 PD patients, taken off their regular treatment for at least 12 hours, received soluble 200 mg LD/50 mg benserazide under stress free conditions. Motor symptoms improved, LD and 3-OMD levels increased, whereas cortisol concentrations started to decrease significantly 30 minutes after LD intake. This reduced cortisol release may result from an overflow of exogenous LD in the brainstem. This hypothetically causes an reduced 5-HT content in neurons projecting to the hypothalamic structures, which are involved in the partial 5-HT dependent central regulation of peripheral cortisol release.
Similar content being viewed by others
References
H Braak U Rub WP Gai K Del Tredici (2003) ArticleTitleIdiopathic Parkinson’s disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen J Neural Transm 110 517–536 Occurrence Handle12721813 Occurrence Handle10.1007/s00702-002-0808-2 Occurrence Handle1:STN:280:DC%2BD3s3gt1GltQ%3D%3D
D Garcia-Borreguero O Larrosa JJ Granizo LY de la WA Hening (2004) ArticleTitleCircadian variation in neuroendocrine response to L-dopa in patients with restless legs syndrome Sleep 27 669–673 Occurrence Handle15283001
GM Halliday PC Blumbergs RG Cotton WW Blessing LB Geffen (1990) ArticleTitleLoss of brainstem serotonin- and substance P-containing neurons in Parkinson’s disease Brain Res 510 104–107 Occurrence Handle1691042 Occurrence Handle10.1016/0006-8993(90)90733-R Occurrence Handle1:STN:280:DyaK3c3htlWrtQ%3D%3D
S Happe T Tings K Helmschmied K Neubert W Wuttke W Paulus C Trenkwalder (2004) ArticleTitleLevodopa treatment does not affect low-dose apomorphine test in patients with Parkinson’s disease Mov Disord 19 1511–1515 Occurrence Handle15390061 Occurrence Handle10.1002/mds.20244
E Hoglund N Kolm S Winberg (2001) ArticleTitleStress-induced changes in brain serotonergic activity, plasma cortisol and aggressive behavior in Arctic charr (Salvelinus alpinus) is counteracted by L-DOPA Physiol Behav 74 381–389 Occurrence Handle11714503 Occurrence Handle10.1016/S0031-9384(01)00571-6 Occurrence Handle1:CAS:528:DC%2BD3MXosFOjtr4%3D
KP Lesch A Hoh HM Schulte M Osterheider T Müller (1991) ArticleTitleLong-term fluoxetine treatment decreases 5-HT1A receptor responsivity in obsessive-compulsive disorder Psychopharmacology (Berl) 105 415–420 Occurrence Handle10.1007/BF02244438 Occurrence Handle1:CAS:528:DyaK3MXmsVyjtro%3D
KP Lesch M Wiesmann A Hoh T Müller J Disselkamp-Tietze M Osterheider HM Schulte (1992) ArticleTitle5-HT1A receptor-effector system responsivity in panic disorder Psychopharmacology (Berl) 106 111–117 Occurrence Handle10.1007/BF02253597 Occurrence Handle1:CAS:528:DyaK38XisFent70%3D
A Lopez A Munoz MJ Guerra JL Labandeira-Garcia (2001) ArticleTitleMechanisms of the effects of exogenous levodopa on the dopamine-denervated striatum Neuroscience 103 639–651 Occurrence Handle11274784 Occurrence Handle10.1016/S0306-4522(00)00588-1 Occurrence Handle1:CAS:528:DC%2BD3MXit1Wgsbg%3D
E Melamed F Hefti DJ Pettibone J Liebman RJ Wurtman (1981) ArticleTitleAromatic L-amino acid decarboxylase in rat corpus striatum: implications for action of L-dopa in parkinsonism Neurology 31 651–655 Occurrence Handle7195482 Occurrence Handle1:CAS:528:DyaL3MXktl2lu7o%3D
E Melamed F Hefti RJ Wurtman (1980) ArticleTitleNonaminergic striatal neurons convert exogenous L-dopa to dopamine in parkinsonism Ann Neurol 8 558–563 Occurrence Handle6260009 Occurrence Handle10.1002/ana.410080603 Occurrence Handle1:CAS:528:DyaL3MXhtFChsLw%3D
S Muhlack D Woitalla J Welnic S Twiehaus H Przuntek T Müller (2004) ArticleTitleChronic levodopa intake increases levodopa plasma bioavailability in patients with Parkinson’s disease Neurosci Lett 363 284–287 Occurrence Handle15182961 Occurrence Handle10.1016/j.neulet.2004.04.012 Occurrence Handle1:CAS:528:DC%2BD2cXks1CjtL4%3D
T Müller C Erdmann S Muhlack D Bremen H Przuntek D Woitalla (2006) ArticleTitleInhibition of catechol-O-methyltransferase contributes to more stable levodopa plasma levels Mov Disord 21 332–336 Occurrence Handle16211593 Occurrence Handle10.1002/mds.20717
P Osei-Owusu A James J Crane KE Scrogin (2005) ArticleTitle5-Hydroxytryptamine 1A receptors in the paraventricular nucleus of the hypothalamus mediate oxytocin and adrenocorticotropin hormone release and some behavioral components of the serotonin syndrome J Pharmacol Exp Ther 313 1324–1330 Occurrence Handle15743927 Occurrence Handle10.1124/jpet.104.082073 Occurrence Handle1:CAS:528:DC%2BD2MXkslekur0%3D
H Philippi J Pohlenz W Grimm T Koffler W Schonberger (2000) ArticleTitleSimultaneous stimulation of growth hormone, adrenocorticotropin and cortisol with L-dopa/L-carbidopa and propranolol in children of short stature Acta Paediatr 89 442–446 Occurrence Handle10830457 Occurrence Handle10.1080/080352500750028168 Occurrence Handle1:STN:280:DC%2BD3cvisV2ktg%3D%3D
B Sabbe W Hulstijn M Maes M Pier S Scharpe F Zitman (2004) ArticleTitlePsychomotor, neuroendocrine and behavioural effects after oral administration of levodopa in normal volunteers Psychiatry Res 128 103–106 Occurrence Handle15450919 Occurrence Handle10.1016/j.psychres.2004.05.014 Occurrence Handle1:CAS:528:DC%2BD2cXnvV2ku7s%3D
C Schüle TC Baghai D Eser P Zwanzger M Jordan R Buechs R Rupprecht (2006) ArticleTitleTime course of hypothalamic-pituitary-adrenocoertical axis activity during treatment with reboxitine and mirtazapine in depressed patients Psychopharmacology 186 601–611 Occurrence Handle16758243 Occurrence Handle10.1007/s00213-006-0382-7 Occurrence Handle1:CAS:528:DC%2BD28XltlOjtb8%3D
GJ Vega RA Miranda G Martinez MV Torrero dJ Lopez (2003) ArticleTitleHyperpigmentation mimicking Laugier syndrome, levodopa therapy and Addison’s disease J Eur Acad Dermatol Venereol 17 324–327 Occurrence Handle10.1046/j.1468-3083.2003.00431.x
B Vizner Z Reiner M Sekso (1983) ArticleTitleEffect of L-dopa on growth hormone, glucose, insulin, and cortisol response in obese subjects Exp Clin Endocrinol 81 41–48 Occurrence Handle6343098 Occurrence Handle1:STN:280:DyaL3s3gvF2itw%3D%3D Occurrence Handle10.1055/s-0029-1210205
HP Vogel R Ketsche (1986) ArticleTitleEffect of hypoglycaemia, TRH and levodopa on plasma growth hormone, prolactin, thyrotropin and cortisol in Parkinson’s disease before and during therapy J Neurol 233 149–152 Occurrence Handle3088217 Occurrence Handle10.1007/BF00314421 Occurrence Handle1:STN:280:DyaL283ltlaltA%3D%3D
R Volpi P Caffarra A Scaglioni D Maestri P Chiodera V Coiro (1994) ArticleTitleRestoration of ACTH/cortisol and LH responses to naloxone by chronic dopaminergic treatment in Parkinson’s disease J Neural Transm Park Dis Dement Sect 7 1–11 Occurrence Handle8579765 Occurrence Handle10.1007/BF02252658 Occurrence Handle1:CAS:528:DyaK2cXlslKks7s%3D
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Müller, T., Welnic, J. & Muhlack, S. Acute levodopa administration reduces cortisol release in patients with Parkinson’s disease. J Neural Transm 114, 347–350 (2007). https://doi.org/10.1007/s00702-006-0552-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00702-006-0552-0